Kurzfassung

Multicentre, multi-country, prospective, observational, postauthorisation safety study to describe the incidence of discontinuaton due to diarrhea within the first 3 month of treatment with Neratinib, in adult breast cancer patientes treated in extended adjuvant in real world setting